216 related articles for article (PubMed ID: 12428222)
1. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
Strand V
Arthritis Rheum; 2002 Nov; 46(11):2836-7. PubMed ID: 12428222
[No Abstract] [Full Text] [Related]
2. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
3. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
[TBL] [Abstract][Full Text] [Related]
4. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
5. Treatment of systemic sclerosis.
Medsger TA
Rheum Dis Clin North Am; 1989 Aug; 15(3):513-31. PubMed ID: 2672135
[TBL] [Abstract][Full Text] [Related]
6. Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature.
Derk CT; Jimenez SA
J Rheumatol; 2003 Jul; 30(7):1616-20. PubMed ID: 12858467
[TBL] [Abstract][Full Text] [Related]
7. [Renal scleroderma crisis. Role of scleroderma vasculopathy in the induction of cutaneous and visceral fibrosis in 2 cases].
Cuchacovich M; Holuigue G; Gatica H; Alvo M; Murray G
Rev Med Chil; 2000 Jan; 128(1):86-92. PubMed ID: 10883527
[TBL] [Abstract][Full Text] [Related]
8. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
Clements PJ; Seibold JR; Furst DE; Mayes M; White B; Wigley F; Weisman MD; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Wong WK
Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
[TBL] [Abstract][Full Text] [Related]
9. Does long-term treatment with D-penicillamine alter calcium and phosphorus metabolism in patients with systemic sclerosis?
Hagdrup H; Serup J; Tvedegaard E
Acta Derm Venereol; 1983; 63(5):447-9. PubMed ID: 6197850
[TBL] [Abstract][Full Text] [Related]
10. [Obliterating bronchiolitis induced by D-penicillamine in the female patient with systemic scleroderma].
Alekperov RT; Avdeev SN; Kotovskaia MA
Ter Arkh; 2004; 76(3):74-6. PubMed ID: 15108466
[No Abstract] [Full Text] [Related]
11. [Treatment of scleroderma].
Mouthon L
Rev Prat; 2002 Nov; 52(17):1915-7. PubMed ID: 12532869
[TBL] [Abstract][Full Text] [Related]
12. D-penicillamine in systemic sclerosis? Yes!
Medsger TA; Lucas M; Wildy KS; Baker C
Scand J Rheumatol; 2001; 30(4):192-4. PubMed ID: 11578011
[TBL] [Abstract][Full Text] [Related]
13. Penicillamine in the treatment of systemic sclerosis.
Clements PJ
Curr Rheumatol Rep; 1999 Oct; 1(1):38-42. PubMed ID: 11123013
[TBL] [Abstract][Full Text] [Related]
14. [D-penicillamine-induced lipoid nephrosis in a patient with scleroderma].
Kitazawa K; Ohseto Y; Kawazumi H; Saito K; Shibata T; Uchida J; Yonekura M; Shiwachi S; Ito S; Sugisaki T
Ryumachi; 1982 Oct; 22(5):397-403. PubMed ID: 7157094
[No Abstract] [Full Text] [Related]
15. Progressive systemic sclerosis and penicillamine.
Rodnan GP
J Rheumatol Suppl; 1981; 7():116-20. PubMed ID: 6939873
[TBL] [Abstract][Full Text] [Related]
16. [Renal involvement in scleroderma].
Boffa JJ; Rossert J
Rev Prat; 2002 Nov; 52(17):1910-4. PubMed ID: 12532868
[TBL] [Abstract][Full Text] [Related]
17. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
[TBL] [Abstract][Full Text] [Related]
18. [Long-term use of D-penicillamine in systemic scleroderma and rheumatoid arthritis].
Guseva NG; Trofimova TM; Oskilko TG; Panasiuk AF; Tarasenkova TA
Klin Med (Mosk); 1986 Jun; 64(6):44-50. PubMed ID: 3747436
[No Abstract] [Full Text] [Related]
19. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
[TBL] [Abstract][Full Text] [Related]
20. 65Zinc absorption in untreated and D-penicillamine-treated patients with generalized scleroderma: determination by whole-body counting technique.
Høyer H; Hvid-Jacobsen K; Weismann K
Acta Derm Venereol; 1982; 62(5):438-40. PubMed ID: 6183898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
